View of statins as antimicrobials in cardiovascular risk modification

Cardiovascular Research

Volumn 102, Issue 3, 2014, Pages 362-374

  Kozarov, Emil ^a,b   Padro, Teresa ^a   Badimon, Lina ^a,c  

^a BIOMEDICAL RESEARCH INSTITUTE SANT PAU IIB SANT PAU   (Spain)

^b NewYork Presbyterian Hospital   (United States)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Atherosclerosis; Inflammation; Microbial infection; Statins

Indexed keywords

ANTIINFECTIVE AGENT; ANTILIPEMIC AGENT; AZITHROMYCIN; CLARITHROMYCIN; CYCLOOXYGENASE 2; DOXYCYCLINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; REACTIVE OXYGEN METABOLITE; ROXITHROMYCIN; C REACTIVE PROTEIN;

ANTIBIOTIC THERAPY; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ATHEROSCLEROSIS; BACTEREMIA; BACTERIAL INFECTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); DRUG EFFECT; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PATHOGENESIS; PERIODONTITIS; PLEIOTROPY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SECONDARY PREVENTION; SEPSIS; VASCULITIS; ANIMAL; CARDIOVASCULAR DISEASES; COMPLICATION;

ANIMALS; ANTI-INFECTIVE AGENTS; ATHEROSCLEROSIS; BACTERIAL INFECTIONS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PERIODONTITIS; SEPSIS;

EID: 84901457172     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvu058     Document Type: Review

References (168)

1. Brown MS, Dana SE, Goldstein JL. Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts by lipoproteins. Proc Natl Acad Sci USA 1973; 70: 2162-2166.
2. Fears R, Richards DH, Ferres H. The effect of compactin, a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme-A reductase activity, on cholesterogenesis and serum cholesterol levels in rats and chicks. Atherosclerosis 1980;35: 439-449.
3. MerxMW, Weber C. Statins: A preventive strike against sepsis in patients with cardiovascular disease? The Lancet 2006;367: 372-373.
4. Shalev V, Goldshtein I, Porath A, Weitzman D, Shemer J, Chodick G. Continuation of statin therapy and primary prevention of nonfatal cardiovascular events. Am J Cardiol 2012;110: 1779-1786.
5. Cappellari M, Bovi P, Moretto G, Zini A, Nencini P, Sessa M, Furlan M, Pezzini A, Orlandi G, Paciaroni M, Tassinari T, Procaccianti G, Di Lazzaro V, Bettoni L, Gandolfo C, Silvestrelli G, Rasura M, Martini G, Melis M, Calloni MV, Chiodo-Grandi F, Beretta S, Guarino M, Altavista MC, Marcheselli S, Galletti G, Adobbati L, Del Sette M, Mancini A, Orrico D, Monaco S, Cavallini A, Sciolla R, Federico F, Scoditti U, Brusaferri F, Grassa C, Specchio L, Bongioanni MR, Sparaco M, Zampolini M, Greco G, Colombo R, Passarella B, Adami A, Consoli D, Toni D. The THRombolysis and STatins (THRaST) study. Neurology 2013;80: 655-661.
6. Echeverri D, Cabrales J. Statins and percutaneous coronary intervention: A complementary synergy. Clin Invest Arterioscler 2013;25: 112-122.
7. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R, Fruchart JC, Tardif JC, Schoenhagen P, Crowe T, Cain V, Wolski K, Goormastic M, Tuzcu EM. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: The ASTEROID trial. JAMA 2006;295: 1556-1565.
8. Corti R, Fayad ZA, Fuster V, Worthley SG, Helft G, Chesebro J, Mercuri M, Badimon JJ. Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: A longitudinal study by high-resolution, noninvasive magnetic resonance imaging. Circulation 2001; 104: 249-252.
9. Watanabe K, Sugiyama S, Kugiyama K, Honda O, Fukushima H, Koga H, Horibata Y, Hirai T, Sakamoto T, Yoshimura M, Yamashita Y, Ogawa H. Stabilization of carotid atheroma assessed by quantitative ultrasound analysis in nonhypercholesterolemic patients with coronary artery disease. J Am Coll Cardiol 2005;46: 2022-2030.
10. Yamagami H, Sakaguchi M, Furukado S, HoshiT, AbeY, HougakuH, Hori M, Kitagawa K. Statin therapy increases carotid plaque echogenicity in hypercholesterolemic patients. Ultrasound Med Biol 2008;34: 1353-1359.
11. Underhill HR, Yuan C, Zhao XQ, Kraiss LW, Parker DL, Saam T, Chu B, Takaya N, Liu F, Polissar NL, Neradilek B, Raichlen JS, Cain VA, Waterton JC, HamarW, Hatsukami TS. Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: A high-resolution magnetic resonance imaging trial. Am Heart J 2008;155: 584 e581-588.
12. Kadoglou NP, Sailer N, Moumtzouoglou A, Kapelouzou A, Gerasimidis T, Liapis CD. Aggressive lipid-lowering is more effective than moderate lipid-lowering treatment in carotid plaque stabilization. J Vasc Surg 2010;51: 114-121.
13. Wehrwein P (ed). Statin use is up, cholesterol levels are down: Are Americans' hearts benefiting? Harvard Health Publications. Boston: Harvard Medical School; 2011. http ://www.health.harvard.edu/blog/statin-use-is-up- cholesterol-levels-are-down-areamericans-hearts-benefiting-201104151518 (18 March 2014).
14. Riccioni G, Sblendorio V. Atherosclerosis: From biology to pharmacological treatment. J Geriatr Cardiol 2012;9: 305-317.
15. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol 2012;32: 2045-2051.
16. Katz JT, Shannon RP. Bacteria and coronary atheroma: More fingerprints but no smoking gun. Circulation 2006;113: 920-922.
17. Libby P. The forgotten majority: Unfinished business in cardiovascular risk reduction. J Am Coll Cardiol 2005;46: 1225-1228.
18. Greenland P, Knoll MD, Stamler J, Neaton JD, Dyer AR, Garside DB, WilsonPW. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA 2003;290: 891-897.
19. Deloukas P, Kanoni S, Willenborg C, Farrall M, Assimes TL, Thompson JR, Ingelsson E, Saleheen D, Erdmann J, Goldstein BA, Stirrups K, Konig IR, Cazier JB, Johansson A, Hall AS, Lee JY, Willer CJ, Chambers JC, Esko T, Folkersen L, Goel A, Grundberg E, Havulinna AS, Ho WK, Hopewell JC, Eriksson N, Kleber ME, Kristiansson K, Lundmark P, Lyytikainen LP, Rafelt S, Shungin D, Strawbridge RJ, Thorleifsson G, Tikkanen E, Van Zuydam N, Voight BF, Waite LL, Zhang W, Ziegler A, Absher D, Altshuler D, Balmforth AJ, Barroso I, Braund PS, Burgdorf C, Claudi-Boehm S, Cox D, Dimitriou M, Do R, Doney AS, Mokhtari NE, Eriksson P, Fischer K, Fontanillas P, Franco-Cereceda A, Gigante B, Groop L, Gustafsson S, Hager J, Hallmans G, Han BG, Hunt SE, Kang HM, Illig T, Kessler T, Knowles JW, Kolovou G, Kuusisto J, Langenberg C, Langford C, Leander K, Lokki ML, Lundmark A, McCarthy MI, Meisinger C, Melander O, Mihailov E, Maouche S, Morris AD, Muller-Nurasyid M, Nikus K, Peden JF, Rayner NW, Rasheed A, Rosinger S, Rubin D, Rumpf MP, Schafer A, Sivananthan M, Song C, Stewart AF, Tan ST, Thorgeirsson G, Schoot CE, Wagner PJ, Wells GA, Wild PS, Yang TP, Amouyel P, Arveiler D, Basart H, Boehnke M, Boerwinkle E, Brambilla P, Cambien F, Cupples AL, de Faire U, Dehghan A, Diemert P, Epstein SE, Evans A, Ferrario MM, Ferrieres J, Gauguier D, Go AS, Goodall AH, Gudnason V, Hazen SL, Holm H, Iribarren C, Jang Y, Kahonen M, Kee F, Kim HS, Klopp N, KoenigW, KratzerW, Kuulasmaa K, Laakso M, Laaksonen R, Lind L, Ouwehand WH, Parish S, Park JE, Pedersen NL, Peters A, Quertermous T, Rader DJ, Salomaa V, Schadt E, Shah SH, Sinisalo J, Stark K, Stefansson K, Tregouet DA, Virtamo J, Wallentin L, Wareham N, Zimmermann ME, Nieminen MS, Hengstenberg C, Sandhu MS, Pastinen T, Syvanen AC, Hovingh GK, Dedoussis G, Franks PW, Lehtimaki T, Metspalu A, Zalloua PA, Siegbahn A, Schreiber S, Ripatti S, Blankenberg SS, Perola M, Clarke R, Boehm BO, O'Donnell C, Reilly MP, Marz W, Collins R, Kathiresan S, Hamsten A, Kooner JS, Thorsteinsdottir U, Danesh J, Palmer CN, Roberts R, Watkins H, Schunkert H, Samani NJ. Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet 2012;45: 25-33.
20. Ross R. Mechanisms of disease: Atherosclerosis-an inflammatory disease.NEngl J Med 1999;340: 115-126.
21. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105: 1135-1143.
22. Epstein SE, Zhu J, Najafi AH, Burnett MS. Insights into the role of infection in atherogenesis and in plaque rupture. Circulation 2009;119: 3133-3141.
23. Lalla E, Lamster IB, Hofmann MA, Bucciarelli L, Jerud AP, Tucker S, Lu Y, Papapanou PN, Schmidt AM. Oral infection with a periodontal pathogen accelerates early atherosclerosis in apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 2003;23: 1405-1411.
24. Amar S, WuSC, Madan M. Is Porphyromonas gingivalis cell invasion required for atherogenesis? Pharmacotherapeutic implications. J Immunol 2009;182: 1584-1592.
25. Jain A, Batista EL Jr, Serhan C, Stahl GL, Van Dyke TE. Role for periodontitis in the progression of lipid deposition in an animal model. Infect Immun 2003;71: 6012-6018.
26. Brodala N, Merricks EP, Bellinger DA, Damrongsri D, Offenbacher S, Beck J, Madianos P, Sotres D, Chang YL, Koch G, Nichols TC. Porphyromonas gingivalis bacteremia induces coronary and aortic atherosclerosis in normocholesterolemic and hypercholesterolemic pigs. Arterioscler Thromb Vasc Biol 2005;25: 1446-1451.
27. Kesavalu L, Lucas AR, Verma RK, Liu L, Dai E, Sampson E, Progulske-Fox A. Increased atherogenesis during Streptococcus mutans infection in ApoE-null mice. J Dent Res 2012; 91: 255-260.
28. Rivera MF, Lee JY, Aneja M, Goswami V, Liu L, Velsko IM, Chukkapalli SS, Bhattacharyya I, Chen H, Lucas AR, Kesavalu LN. Polymicrobial infection with major periodontal pathogens induced periodontal disease and aortic atherosclerosis in hyperlipidemic ApoE(null) mice. PLoS ONE 2013;8: E57178.
29. Gibson FC 3rd, Hong C, Chou HH, Yumoto H, Chen J, Lien E, Wong J, Genco CA. Innate immune recognition of invasive bacteria accelerates atherosclerosis in apolipoprotein E-deficient mice. Circulation 2004;109: 2801-2806.
30. Elkind MSV, Ramakrishnan P, Moon YP, Boden-Albala B, LiuKM, Spitalnik SL, Rundek T, Sacco RL, Paik MC. Infectious burden and risk of stroke: The Northern Manhattan Study. Arch Neurol 2010;67: 33-38.
31. Desvarieux M, Demmer RT, Rundek T, Boden-Albala B, Jacobs DR Jr, Papapanou PN, Sacco RL. Relationship between periodontal disease, tooth loss, and carotid artery plaque: The Oral Infections and Vascular Disease Epidemiology Study (INVEST). Stroke 2003;34: 2120-2125.
32. Desvarieux M, Demmer RT, Rundek T, Boden-Albala B, Jacobs DR Jr, Sacco RL, Papapanou PN. Periodontal microbiota and carotid intima-media thickness: The Oral Infections and Vascular Disease Epidemiology Study (INVEST). Circulation 2005;111: 576-582.
33. Offenbacher S, Beck JD. A perspective on the potential cardioprotective benefits of periodontal therapy. Am Heart J 2005;149: 950-954.
34. Mattila KJ, Pussinen PJ, Paju S. Dental infections and cardiovascular diseases: A review. J Periodontol 2005;76: 2085-2088.
35. Kebschull M, Demmer RT, Papapanou PN. "Gum bug, leave my heart alone!"-epidemiologic and mechanistic evidence linking periodontal infections and atherosclerosis. J Dent Res 2010;89: 879-902.
36. Hayashi C, Gudino CV, Gibson FC III, Genco CA. Review: Pathogen-induced inflammation at sites distant from oral infection: Bacterial persistence and induction of cellspecific innate immune inflammatory pathways. Mol Oral Microbiol 2010;25: 305-316.
37. Kallio KA, Hyvarinen K, Kovanen PT, Jauhiainen M, Pussinen PJ. Very low density lipoproteins derived from periodontitis patients facilitate macrophage activation via lipopolysaccharide function. Metabolism 2013;62: 661-668.
38. Tonetti MS, Van Dyke TE. Periodontitis and atherosclerotic cardiovascular disease: Consensus report of the Joint EFP/AAPWorkshop on Periodontitis and Systemic Diseases. J Periodontol 2013;84: S24-S29.
39. Reyes L, Herrera D, Kozarov E, Roldan S, Progulske-Fox A. Periodontal bacterial invasion and infection: Contribution to atherosclerotic pathology. J Clin Periodontol 2013; 40(Suppl 14): S30-S50.
40. Hayashi C, Viereck J, Hua N, Phinikaridou A, Madrigal AG, Gibson FC III, Hamilton JA, Genco CA. Porphyromonas gingivalis accelerates inflammatory atherosclerosis in the innominate artery of ApoE deficient mice. Atherosclerosis 2011;215: 52-59.
41. Giacona MB, Papapanou PN, Lamster IB, Rong LL, D'Agati VD, Schmidt AM, Lalla E. Porphyromonas gingivalis induces its uptake by human macrophages and promotes foam cell formation in vitro. FEMS Microbiol Lett 2004;241: 95-101.
42. Hayashi C, Madrigal AG, Liu X, Ukai T, Goswami S, Gudino CV, Gibson FC III, Genco CA. Pathogen-mediated inflammatory atherosclerosis is mediated in part via Toll-like receptor 2-induced inflammatory responses. J Innate Immun 2010.
43. Hashizume T, Kurita-Ochiai T, Yamamoto M. Porphyromonas gingivalis stimulates monocyte adhesion to human umbilical vein endothelial cells. FEMS Immunol Med Microbiol 2011;62: 57-65.
44. Papapanagiotou D, Nicu EA, Bizzarro S, Gerdes VE, Meijers JC, Nieuwland R, van der Velden U, Loos BG. Periodontitis is associated with platelet activation. Atherosclerosis 2009;202: 605-611.
45. Yu KM, Inoue Y, UmedaM, Terasaki H, Chen ZY, Iwai T. The periodontal anaerobe Porphyromonas gingivalis induced platelet activation and increased aggregation in whole blood by rat model. Thrombosis Res. 2011;127: 418-425.
46. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men [see comments] [published erratum appears inNEngl J Med 1997 Jul 31;337(5): 356]. NEngl J Med 1997;336: 973-979.
47. Joshipura KJ, Wand HC, Merchant AT, Rimm EB. Periodontal disease and biomarkers related to cardiovascular disease. J Dent Res 2004;83: 151-155.
48. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, KruyerW, Gotto AM Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615-1622.
49. Ridker PM, Friedewald VE, Davidson MH, Willerson JT, Roberts WC. The editor's roundtable: The JUPITER trial-initial results and clinical implications. Am J Cardiol 2009;103: 1417-1425.
50. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359: 2195-2207.
51. Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, Danesh J. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: An individual participant meta-analysis. Lancet 2010;375: 132-140.
52. Leishman SJ, Ford PJ, Do HL, Palmer JE, Heng NC, West MJ, Seymour GJ, Cullinan MP. Periodontal pathogen load and increased antibody response to heat shock protein 60 in patients with cardiovascular disease. J Clin Periodontol 2012;39: 923-930.
53. Kozarov E, Dorn B, Shelburne C, Dunn W, Progulske-Fox A. Human atherosclerotic plaque contains viable invasive Porphyromonas gingivalis and Actinobacillus actinomycetemcomitans. Arterioscler Thromb Vasc Biol 2005;25: E17-e18.
54. Haraszthy VI, Zambon JJ, Trevisan M, Zeid M, Genco RJ. Identification of periodontal pathogens in atheromatous plaques. J Periodontol 2000;71: 1554-1560.
55. Ott SJ, El Mokhtari NE, Musfeldt M, Hellmig S, Freitag S, Rehman A, Kuhbacher T, Nikolaus S, Namsolleck P, Blaut M, Hampe J, Sahly H, Reinecke A, Haake N, Gunther R, Kruger D, Lins M, Herrmann G, Folsch UR, Simon R, Schreiber S. Detection of diverse bacterial signatures in atherosclerotic lesions of patients with coronary heart disease. Circulation 2006;113: 929-937.
56. Kozarov E, Sweier D, Shelburne C, Progulske-Fox A, Lopatin D. Detection of bacterial DNA in atheromatous plaques by quantitative PCR. Microbes Infect 2006;8: 687-693.
57. Jackson LA, Campbell LA, Kuo CC, Rodriguez DI, Lee A, Grayston JT. Isolation of Chlamydia pneumoniae from a carotid endarterectomy specimen. J Infect Dis 1997;176: 292-295.
58. Rafferty B, Jönsson D, Kalachikov S, Demmer RT, Nowygrod R, Elkind MS, Bush H Jr, Kozarov E. Impact of monocytic cells on recovery of uncultivable bacteria from atherosclerotic lesions. J Intern Med 2011;270: 273-280.
59. Kozarov E. Bacterial invasion of vascular cell types: Vascular infectology and atherogenesis. Future Cardiol 2012;8: 123-138.
60. Rosenfeld ME. Inflammation and atherosclerosis: Direct versus indirect mechanisms. Curr Opin Pharmacol 2013;13: 154-160.
61. Reyes L, HerreraD, Kozarov E, Rolda S, Progulske-Fox A. Periodontal bacterial invasion and infection: Contribution to atherosclerotic pathology. J Periodontol 2013;84: S30-S50.
62. Vita JA, Loscalzo J. Shouldering the risk factor burden: Infection, atherosclerosis, and the vascular endothelium. Circulation 2002;106: 164-166.
63. Parchure N, Zouridakis EG, Kaski JC. Effect of azithromycin treatment on endothelial function in patients with coronary artery disease and evidence of Chlamydia pneumoniae infection. Circulation 2002;105: 1298-1303.
64. Muhlestein JB, Anderson JL, Carlquist JF, Salunkhe K, Horne BD, Pearson RR, Bunch TJ, Allen A, Trehan S, Nielson C. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: Primary clinical results of the ACADEMIC study. Circulation 2000;102: 1755-1760.
65. Zahn R, Schneider S, Frilling B, Seidl K, Tebbe U, Weber M, Gottwik M, Altmann E, Seidel F, Rox J, Hoffler U, Neuhaus KL, Senges J. Antibiotic therapy after acute myocardial infarction: A prospective randomized study. Circulation 2003;107: 1253-1259.
66. O'Connor CM, Dunne MW, Pfeffer MA, Muhlestein JB, Yao L, Gupta S, Benner RJ, Fisher MR, Cook TD. Azithromycin for the secondary prevention of coronary heart disease events: The WIZARD study: A randomized controlled trial. JAMA 2003;290: 1459-1466.
67. Grayston JT, Kronmal RA, Jackson LA, Parisi AF, Muhlestein JB, Cohen JD, Rogers WJ, Crouse JR, Borrowdale SL, Schron E, Knirsch C. Azithromycin for the secondary prevention of coronary events. N Engl J Med 2005;352: 1637-1645.
68. Vainas T, Stassen FR, Schurink GW, Tordoir JH, Welten RJ, van den Akker LH, Kurvers HA, Bruggeman CA, Kitslaar PJ. Secondary prevention of atherosclerosis through Chlamydia pneumoniae eradication (SPACE Trial): A randomised clinical trial in patients with peripheral arterial disease. Eur J Vasc Endovasc Surg 2005;29: 403-411.
69. Joensen JB, Juul S, Henneberg E, Thomsen G, Ostergaard L, Lindholt JS. Can long-term antibiotic treatment prevent progression of peripheral arterial occlusive disease? A large, randomized, double-blinded, placebo-controlled trial. Atherosclerosis 2008;196: 937-942.
70. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin inmale survivors of myocardial infarction. Circulation 1997;96: 404-407.
71. Gurfinkel E, Bozovich G, Beck E, Testa E, Livellara B, Mautner B. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS Study. Eur Heart J 1999;20: 121-127.
72. Anderson JL, Muhlestein JB, Carlquist J, Allen A, Trehan S, Nielson C, Hall S, Brady J, Egger M, Horne B, Lim T. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: The Azithromycin in CoronaryArtery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study. Circulation 1999;99: 1540-1547.
73. Mosorin M, Juvonen J, Biancari F, Satta J, Surcel HM, Leinonen M, Saikku P, Juvonen T. Use of doxycycline to decrease the growth rate of abdominal aortic aneurysms: A randomized, double-blind, placebo-controlled pilot study. J Vasc Surg 2001;34: 606-610.
74. Neumann F, Kastrati A, Miethke T, Pogatsa-Murray G, Mehilli J, Valina C, Jogethaei N, da Costa CP, Wagner H, Schomig A. Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3): A randomised, double-blind, placebo-controlled trial. Lancet 2001;357: 2085-2089.
75. Leowattana W, Bhuripanyo K, Singhaviranon L, Akaniroj S, Mahanonda N, Samranthin M, Pokum S. Roxithromycin in prevention of acute coronary syndrome associated with Chlamydia pneumoniae infection: A randomized placebo controlled trial. J Med Assoc Thailand 2001;84(Suppl 3): S669-S675.
76. Wiesli P, CzerwenkaW, Meniconi A, Maly FE, Hoffmann U, VetterW, Schulthess G. Roxithromycin treatment prevents progression of peripheral arterial occlusive disease in Chlamydia pneumoniae seropositive men: A randomized, double-blind, placebo-controlled trial. Circulation 2002;105: 2646-2652.
77. Sander D, Winbeck K, Klingelhofer J, Etgen T, Conrad B. Reduced progression of early carotid atherosclerosis after antibiotic treatment and Chlamydia pneumoniae seropositivity. Circulation 2002;106: 2428-2433.
78. Sinisalo J, Mattila K, Valtonen V, Anttonen O, Juvonen J, Melin J, Vuorinen-Markkola H, Nieminen MS. Effect of 3 months of antimicrobial treatment with clarithromycin in acute non-q-wave coronary syndrome. Circulation 2002;105: 1555-1560.
79. Stone AF, Mendall MA, Kaski JC, Edger TM, Risley P, Poloniecki J, Camm AJ, Northfield TC. Effect of treatment for Chlamydia pneumoniae and Helicobacter pylori on markers of inflammation and cardiac events in patients with acute coronary syndromes: South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA). Circulation 2002;106: 1219-1223.
80. da Costa CP, Neumann FJ, Kastrati A, Stallforth I, Schmid M, Joghetai N, Prebeck S, Wagner H, Miethke T. Role of IgG-seropositivity to Chlamydia pneumoniae in early thrombotic events after coronary stent placement. Atherosclerosis 2003;166: 171-176.
81. Cercek B, Shah PK, NocM, Zahger D, Zeymer U, Matetzky S, Maurer G, MahrerP. Effect of short-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial: A randomised controlled trial. Lancet 2003;361: 809-813.
82. Burkhardt U, Zahn R, Hoffler U, Siegler KE, Frilling B, Weber M, Gottwik M, Wehr M, Seidel F, Rosocha S, Tebbe U, Senges J. Antibody levels against Chlamydia pneumoniae and outcome of roxithromycin therapy in patients with acute myocardial infarction. Results from a sub-study of the randomised Antibiotic Therapy in Acute Myocardial Infarction (ANTIBIO) trial. Z Kardiol2004;93: 671-678.
83. Hillis GS, Pearson CV, Harding SA, Sutherland S, Ludlam CA, Marioni JC, Prescott RJ, Fox KA, Flapan AD. Effects of a brief course of azithromycin on soluble cell adhesion molecules and markers of inflammation in survivors of an acute coronary syndrome: A double-blind, randomized, placebo-controlled study. Am Heart J 2004;148: 72-79.
84. Krayenbuehl PA, Wiesli P, Maly FE, VetterW, Schulthess G. Progression of peripheral arterial occlusive disease is associated with Chlamydia pneumoniae seropositivity and can be inhibited by antibiotic treatment. Atherosclerosis 2005;179: 103-110.
85. Berg HF, Maraha B, Scheffer GJ, Quarles-van Ufford M, Vandenbroucke-Grauls CM, Peeters MF, Kluytmans JA. Treatment with clarithromycin prior to coronary artery bypass graft surgery does not prevent subsequent cardiac events. Clin Infect Dis 2005; 40: 358-365.
86. Karlsson L, Gnarpe J, Bergqvist D, Lindback J, Parsson H. The effect of azithromycin and Chlamydophilia pneumonia infection on expansion of small abdominal aortic aneurysms-a prospective randomized double-blind trial. J Vasc Surg 2009;50: 23-29.
87. Takagi H, Matsui M, Umemoto T. A meta-analysis of clinical studies of statins for prevention of abdominal aortic aneurysm expansion. J Vasc Surg 2010;52: 1675-1681.
88. Takagi H, Yamamoto H, Iwata K, Goto S, Umemoto T. Effects of statin therapy on abdominal aortic aneurysm growth: A meta-analysis and meta-regression of observational comparative studies. Eur J Vasc Endovasc Surg 2012;44: 287-292.
89. Takagi H, Umemoto T. Reply to 'Comment on effects of statin therapy on abdominal aortic aneurysm growth: A meta-analysis and meta-regression of observational comparative studies'. Eur J Vasc Endovasc Surg 2013;45: 98-99.
90. Gieffers J, Füllgraf H, Jahn J, Klinger M, Dalhoff K, Katus HA, SolbachW, Maass M. Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment. Circulation 2001;103: 351-356.
91. Liu C, Waters DD. Chlamydia pneumoniae and atherosclerosis: From Koch postulates to clinical trials. Prog Cardiovasc Dis 2005;47: 230-239.
92. Gieffers J, Rupp J, Gebert A, SolbachW, Klinger M. First-choice antibiotics at subinhibitory concentrations induce persistence of Chlamydia pneumoniae. Antimicrob Agents Chemother 2004;48: 1402-1405.
93. Espinola-Klein C, Rupprecht HJ, Blankenberg S, Bickel C, Kopp H, Rippin G, Victor A, Hafner G, SchlumbergerW, Meyer J. Impact of infectious burden on extent and longterm prognosis of atherosclerosis. Circulation 2002;105: 15-21.
94. Ridker PM. On evolutionary biology, inflammation, infection, and the causes of atherosclerosis. Circulation 2002;105: 2-4.
95. Badimon L, StoreyRF, Vilahur G. Update on lipids, inflammation and atherothrombosis. Thromb Haemost 2011;105(Suppl 1): S34-S42.
96. Badimon L, Vilahur G. LDL-cholesterol versus HDL-cholesterol in the atherosclerotic plaque: Inflammatory resolution versus thrombotic chaos. Ann NY Acad Sci 2012;1254: 18-32.
97. BirckMM, Saraste A, Hyttel P, Odermarsky M, Liuba P, SaukkoP, Hansen AK, Pesonen E. Endothelial cell death and intimal foam cell accumulation in the coronary artery of infected hypercholesterolemic minipigs. J Cardiovasc Transl Res 2013;6: 579-587.
98. Werner N, Nickenig G, Laufs U. Pleiotropic effects of HMG-CoA reductase inhibitors. Basic Res Cardiol 2002;97: 105-116.
99. Liao JK. Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol 2005;96: 24f-33f.
100. LaheraV, Goicoechea M, de Vinuesa SG, Miana M, de las Heras N, CachofeiroV, Luno J. Endothelial dysfunction, oxidative stress and inflammation in atherosclerosis: Beneficial effects of statins. Curr Med Chem 2007;14: 243-248.
101. Wang CY, Liu PY, Liao JK. Pleiotropic effects of statin therapy: Molecular mechanisms and clinical results. Trends Mol Med 2008;14: 37-44.
102. Blum A, Shamburek R. The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis. Atherosclerosis 2009;203: 325-330.
103. Hennessy E, Mooij MJ, Legendre C, Reen FJ, O'Callaghan J, Adams C, O'Gara F. Statins inhibit in vitro virulence phenotypes of Pseudomonas aeruginosa. J Antibiot (Tokyo) 2013; 66: 99-101.
104. Jerwood S, Cohen J. Unexpected antimicrobial effect of statins. J Antimicrob Chemother 2008;61: 362-364.
105. Qiao J, Kontoyiannis DP, Wan Z, Li R, LiuW. Antifungal activity of statins against Aspergillus species. Med Mycol 2007;45: 589-593.
106. Pradines B, Torrentino-Madamet M, Fontaine A, Henry M, Baret E, Mosnier J, Briolant S, Fusai T, Rogier C. Atorvastatin is 10-fold more active in vitro than other statins against Plasmodium falciparum. Antimicrob Agents Chemother 2007;51: 2654-2655.
107. Nyilasi I, Kocsube S, Krizsan K, Galgoczy L, Pesti M, Papp T, Vagvolgyi C. In vitro synergistic interactions of the effects of various statins and azoles against some clinically important fungi. FEMS Microbiol Lett 2010;307: 175-184.
108. Bergman P, Linde C, Putsep K, Pohanka A, Normark S, Henriques-Normark B, Andersson J, Bjorkhem-Bergman L. Studies on the antibacterial effects of statins-in vitro and in vivo. PLoS ONE 2011;6: E24394.
109. CobanAY, TekeliHO, Guney AK, Durupinar B. Investigation of the in vitro antibacterial effects of statins. Mikrobiyol Bul 2010;44: 161-163.
110. Farmer AR, Murray CK, Mende K, Akers KS, Zera WC, Beckius ML, Yun HC. Effect of HMG-CoA reductase inhibitors on antimicrobial susceptibilities for gram-negative rods. J Basic Microbiol 2013;53: 336-339.
111. Erkkila L, Jauhiainen M, Laitinen K, Haasio K, Tiirola T, Saikku P, Leinonen M. Effect of simvastatin, an established lipid-lowering drug, on pulmonary Chlamydia pneumoniae infection in mice. Antimicrob Agents Chemother 2005;49: 3959-3962.
112. Xiong Q, Wang X, Rikihisa Y. High-cholesterol diet facilitates Anaplasma phagocytophilum infection and up-regulates macrophage inflammatory protein-2 and CXCR2 expression in apolipoprotein E-deficient mice. J Infect Dis 2007;195: 1497-1503.
113. Parihar SP, Guler R, Khutlang R, Lang DM, Hurdayal R, Mhlanga MM, Suzuki H, Marais AD, Brombacher F. Statin therapy reduces Mycobacterium tuberculosis infection in human macrophages and in mice by enhancing autophagy and phagosome maturation. J Infect Dis 2013.
114. Silva RR, Shrestha-Bajracharya D, Almeida-Leite CM, Leite R, Bahia MT, Talvani A. Short-term therapy with simvastatin reduces inflammatory mediators and heart inflammation during the acute phase of experimental Chagas disease. Mem Inst Oswaldo Cruz 2012;107: 513-521.
115. Leal SM Jr, Roy S, Vareechon C, Carrion S, Clark H, Lopez-Berges MS, Di Pietro A, Schrettl M, Beckmann N, Redl B, Haas H, Pearlman E. Targeting iron acquisition blocks infection with the fungal pathogens Aspergillus fumigatus and Fusarium oxysporum. PLoS Pathog 2013;9: E1003436.
116. Jong A, Wu CH, Gonzales-Gomez I, Kwon-Chung KJ, Chang YC, Tseng HK, Cho WL, Huang SH. Hyaluronic acid receptor CD44 deficiency is associated with decreased Cryptococcus neoformans brain infection. J Biol Chem 2012;287: 15298-15306.
117. Souraud JB, Briolant S, Dormoi J, Mosnier J, Savini H, Baret E, Amalvict R, Soulard R, Rogier C, Pradines B. Atorvastatin treatment is effective when used in combination with mefloquine in an experimental cerebral malaria murine model.Malar J 2012;11: 13.
118. Radigan KA, Urich D, Misharin AV, Chiarella SE, Soberanes S, Gonzalez A, Perlman H, Wunderink RG, Budinger GR, Mutlu GM. The effect of rosuvastatin in a murine model of influenza A infection. PLoS ONE 2012;7: E35788.
119. Liappis AP, Kan VL, Rochester CG, Simon GL. The effect of statins on mortality in patients with bacteremia. Clin Infect Dis 2001;33: 1352-1357.
120. Dinakaran V, John L, Rathinavel A, Gunasekaran P, Rajendhran J. Prevalence of bacteria in the circulation of cardiovascular disease patients, Madurai, India. Heart Lung Circ 2012; 21: 281-283.
121. Shyamsundar M, McKeown ST, O'Kane CM, Craig TR, Brown V, Thickett DR, Matthay MA, Taggart CC, Backman JT, Elborn JS, McAuley DF. Simvastatin decreases lipopolysaccharide-induced pulmonary inflammation in healthy volunteers. Am J Respir Crit Care Med 2009;179: 1107-1114.
122. Fehr T, Kahlert C, Fierz W, Joller-Jemelka HI, Riesen WF, Rickli H, Wuthrich RP, Ammann P. Statin-induced immunomodulatory effects on human T cells in vivo. Atherosclerosis 2004;175: 83-90.
123. Niessner A, Steiner S, Speidl WS, Pleiner J, Seidinger D, Maurer G, Goronzy JJ, Weyand CM, Kopp CW, Huber K, Wolzt M, Wojta J. Simvastatin suppresses endotoxin-induced upregulation of toll-like receptors 4 and 2 in vivo. Atherosclerosis 2006;189: 408-413.
124. NseirW, Khateeb J, Abu-Elheja O, Jihad B, Assy N. The impact of prior long-term versus short-term statin use on the mortality of bacteraemic patients. Infection 2012;40: 41-48.
125. Doshi SM, Kulkarni PA, Liao JM, Rueda AM, Musher DM. The impact of statin and macrolide use on early survival in patients with pneumococcal pneumonia. Am J Med Sci 2013;345: 173-177.
126. Wunderink RG, Mandell L. Adjunctive therapy in community-acquired pneumonia. Semin Respir Crit Care Med 2012;33: 311-318.
127. Novack V, MacFadyen J, Malhotra A, Almog Y, Glynn RJ, Ridker PM. The effect of rosuvastatin on incident pneumonia: Results from the JUPITER trial. Can Med Assoc J 2012; 184: E367-E372.
128. Motzkus-Feagans CA, Pakyz A, Polk R, Gambassi G, Lapane KL. Statin use and the risk of Clostridium difficile in academic medical centres. Gut 2012;61: 1538-1542.
129. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29: 1303-1310.
130. Sands KE, Bates DW, Lanken PN, Graman PS, Hibberd PL, Kahn KL, Parsonnet J, Panzer R, Orav EJ, Snydman DR, Black E, Schwartz JS, Moore R, Johnson BL Jr, Platt R. Epidemiology of sepsis syndrome in 8 academic medical centers. JAMA 1997; 278: 234-240.
131. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003;348: 1546-1554.
132. Osuchowski MF, Welch K, Yang H, Siddiqui J, Remick DG. Chronic sepsis mortality characterized by an individualized inflammatory response. J Immunol 2007;179: 623-630.
133. Hackam DG, Mamdani M, Li P, Redelmeier DA. Statins and sepsis in patients with cardiovascular disease: A population-based cohort analysis. Lancet 2006;367: 413-418.
134. Merx MW, Liehn EA, Janssens U, Lutticken R, Schrader J, Hanrath P, Weber C. HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis. Circulation 2004;109: 2560-2565.
135. Terblanche M, Almog Y, Rosenson RS, Smith TS, Hackam DG. Statins: Panacea for sepsis? Lancet Infect Dis 2006;6: 242-248.
136. Calisto KL, Carvalho Bde M, Ropelle ER, Mittestainer FC, Camacho AC, Guadagnini D, Carvalheira JB, Saad MJ. Atorvastatin improves survival in septic rats: Effect on tissue inflammatory pathway and on insulin signaling. PLoS ONE 2010;5: E14232.
137. Leung S, Pokharel R, Gong MN. Statins and outcomes in patients with bloodstream infection: A propensity-matched analysis. Crit Care Med 2012;40: 1064-1071.
138. NseirW, Diab H, Mahamid M, Abu-Elheja O, Samara M, Abid A, Mograbi J. Randomised clinical trial: Simvastatin as adjuvant therapy improves significantly the Helicobacter pylori eradication rate-a placebo-controlled study. Aliment Pharmacol Ther 2012;36: 231-238.
139. Sangwan A, Tewari S, Singh H, Sharma RK, Narula SC. Periodontal status and hyperlipidemia: Statin users versus non-users. J Periodontol 2013;84: 3-12.
140. Subramanian S, Emami H, Vucic E, Singh P, Vijayakumar J, Fifer KM, Alon A, Shankar SS, Farkouh M, Rudd JH, Fayad ZA, Van Dyke TE, Tawakol A. High dose atorvastatin reduces periodontal inflammation: A novel pleiotropic effect of statins. J Am Coll Cardiol 2013;62: 2382-2391.
141. Quist-Paulsen P. Statins and inflammation: An update. Curr Opin Cardiol 2010;25: 399-405.
142. Keizer HG. The 'Mevalonate hypothesis': A cholesterol-independent alternative for the etiology of atherosclerosis. Lipids Health Dis 2012;11: 149.
143. Alegret M, Silvestre JS. Pleiotropic effects of statins and related pharmacological experimental approaches. Methods Find Exp Clin Pharmacol 2006;28: 627-656.
144. Borysiewicz E, Fil D, KonatGW. Rho proteins are negative regulators of TLR2, TLR3, and TLR4 signaling in astrocytes. J Neurosci Res 2009;87: 1565-1572.
145. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: Therapeutic challenges and opportunities. J Clin Invest 2006;116: 4-15.
146. Alvarez Y, Municio C, Alonso S, San Roman JA, Sanchez Crespo M, Fernandez N. Cyclooxygenase-2 induced by zymosan in human monocyte-derived dendritic cells shows high stability, and its expression is enhanced by atorvastatin. J Pharmacol Exp Ther 2009;329: 987-994.
147. Grommes J, Vijayan S, Drechsler M, Hartwig H, Morgelin M, Dembinski R, Jacobs M, Koeppel TA, Binnebosel M, Weber C, Soehnlein O. Simvastatin reduces endotoxin-induced acute lung injury by decreasing neutrophil recruitment and radical formation. PLoS ONE 2012;7: E38917.
148. Tsukimori K, Tsushima A, Fukushima K, Nakano H, Wake N. Neutrophil-derived reactive oxygen species can modulate neutrophil adhesion to endothelial cells in preeclampsia. Am J Hypertens 2008;21: 587-591.
149. Chiarugi P, Pani G, Giannoni E, Taddei L, Colavitti R, Raugei G, Symons M, Borrello S, Galeotti T, Ramponi G. Reactive oxygen species as essential mediators of cell adhesion: The oxidative inhibition of aFAKtyrosine phosphatase is required for cell adhesion. J Cell Biol 2003;161: 933-944.
150. Marschang P, Friedrich GJ, Ditlbacher H, Stoeger A, Nedden DZ, Kirchmair R, Dienstl A, Pachinger O, Patsch JR. Reduction of soluble P-selectin by statins is inversely correlated with the progression of coronary artery disease. Int J Cardiol 2006;106: 183-190.
151. Ray KK, Cannon CP, Ganz P. Beyond lipid lowering: What have we learned about the benefits of statins from the acute coronary syndromes trials? Am J Cardiol 2006;98: 18p-25p.
152. Montecucco F, Quercioli A, Mirabelli-Badenier M, Viviani GL, Mach F. Statins in the treatment of acute ischemic stroke. Curr Pharm Biotechnol 2012;13: 68-76.
153. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, Badimon JJ, Stefanadis C, Moreno P, Pasterkamp G, Fayad Z, Stone PH, Waxman S, Raggi P, Madjid M, Zarrabi A, Burke A, Yuan C, Fitzgerald PJ, Siscovick DS, de Korte CL, Aikawa M, Airaksinen KE, Assmann G, Becker CR, Chesebro JH, Farb A, Galis ZS, Jackson C, Jang IK, KoenigW, Lodder RA, March K, Demirovic J, Navab M, Priori SG, Rekhter MD, Bahr R, Grundy SM, Mehran R, Colombo A, Boerwinkle E, Ballantyne C, Insull W Jr, Schwartz RS, Vogel R, Serruys PW, Hansson GK, Faxon DP, Kaul S, Drexler H, Greenland P, Muller JE, Virmani R, Ridker PM, Zipes DP, Shah PK, Willerson JT. From vulnerable plaque to vulnerable patient: A call for new definitions and risk assessment strategies: Part II. Circulation 2003;108: 1772-1778.
154. Tleyjeh IM, Kashour T, Hakim FA, Zimmerman VA, Erwin PJ, Sutton AJ, Ibrahim T. Statins for the prevention and treatment of infections: A systematic review and meta-analysis. Arch Intern Med 2009;169: 1658-1667.
155. Tleyjeh IM, Alasmari FA, Bin Abdulhak AA, Riaz M, Garbati MA, Erwin PJ, Kashour T, Al-Mallah MH, Baddour LM. Association between preoperative statin therapy and postoperative infectious complications in patients undergoing cardiac surgery: A systematic review and meta-analysis. Infect Control Hosp Epidemiol 2012;33: 1143-1151.
156. Khan AR, Riaz M, Bin Abdulhak AA, Al-Tannir MA, Garbati MA, Erwin PJ, Baddour LM, Tleyjeh IM. The role of statins in prevention and treatment of community acquired pneumonia: A systematic review and meta-analysis. PLoS ONE 2013;8: E52929.
157. Brealey DA, Singer M, Terblanche M. Potential metabolic consequences of statins in sepsis. Crit Care Med 2011;39: 1514-1520.
158. Murugan R, Weissfeld L, Yende S, Singbartl K, Angus DC, Kellum JA. Association of statin use with risk and outcome of acute kidney injury in community-acquired pneumonia. Clin J Am Soc Nephrol 2012;7: 895-905.
159. Janda S, Park K, FitzGerald JM, Etminan M, Swiston J. Statins in COPD: A systematic review. Chest 2009;136: 734-743.
160. Mastaglia FL, Needham M. Update on toxic myopathies. Curr Neurol Neurosci Rep 2012; 12: 54-61.
161. Ahmad S, Madsen CS, Stein PD, Janovitz E, Huang C, Ngu K, Bisaha S, Kennedy LJ, Chen BC, Zhao R, Sitkoff D, Monshizadegan H, Yin X, Ryan CS, Zhang R, Giancarli M, Bird E, Chang M, Chen X, Setters R, Search D, Zhuang S, Nguyen-Tran V, Cuff CA, Harrity T, Darienzo CJ, Li T, Reeves RA, Blanar MA, Barrish JC, Zahler R, Robl JA. (3R, 5S, E)-7-(4-(4-fluorophenyl)-6-isopropyl-2- (methyl (1-methyl-1h-1, 2, 4-triazol-5-yl)amino)pyrimidin-5-yl)-3, 5-dihydroxyhept-6-enoic acid (BMS-644950): A rationally designed orally efficacious 3-hydroxy-3-methylglutaryl coenzyme-a reductase inhibitor with reduced myotoxicity potential. J Med Chem 2008;51: 2722-2733.
162. Pfefferkorn JA. 'Muscle-sparing' statins: Preclinical profiles and future clinical use. Curr OpinInvest Drugs 2009;10: 245-252.
163. Pfefferkorn JA. Novel 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: A patent review. Expert Opin Therap Patents 2011;21: 187-203.
164. Janda S, Young A, Fitzgerald JM, EtminanM, Swiston J. The effect of statins on mortality from severe infections and sepsis: A systematic review and meta-analysis. J Crit Care 2010;25:e657-e662.
165. Ridker PM. Testing the inflammatory hypothesis of atherothrombosis: Scientific rationale for the cardiovascular inflammation reduction trial (CIRT). J Thromb Haemost 2009; 7(Suppl 1): 332-339.
166. RidkerPM, ThurenT, ZalewskiA, Libby P. Interleukin-1beta inhibition andthe prevention of recurrent cardiovascular events: Rationale and design of the Canakinumab AntiinflammatoryThrombosisOutcomes Study (CANTOS).AmHeart J 2011;162: 597-605.
167. Koenig W. High-sensitivity C-reactive protein and atherosclerotic disease: From improved risk prediction to risk-guided therapy. Int J Cardiol 2013;168: 5126-5134.
168. GoAS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, BordenWB, Bravata DM, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Magid D, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER, Moy CS, Mussolino ME, Nichol G, Paynter NP, Schreiner PJ, Sorlie PD, Stein J, Turan TN, Virani SS, Wong ND, Woo D, Turner MB. Heart disease and stroke statistics-2013 update: A report from the American Heart Association. Circulation 2013;127: E6-e245.